ArticleJMIR research protocols2018

Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum-Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial.

Goshi Nishimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.